Blog
RSS FeedPosted by Michael Wonder on 05 Aug 2016
PBAC post-market reviews of chronic obstructive pulmonary disease medicines and ezetimibe
5 August 2016 - The public submission process is now closed. ...
Posted by Michael Wonder on 05 Aug 2016
PBAC Guidelines review update
5 August 2016 - The PBAC Guidelines Review is anticipated to be completed by November 2016. ...
Posted by Michael Wonder on 04 Aug 2016
NICE issues draft guidance on the use of lesinurad
3 August 2016 - NICE has issued draft guidance on the use of lesinurad (Zurampic) for the treatment of patients ...
Posted by Michael Wonder on 04 Aug 2016
NICE draft guidance recommends new drug for people with ankylosing spondylitis
4 August 2016 - New draft guidance from NICE means thousands of people with back condition ankylosing spondylitis will soon have ...
Posted by Michael Wonder on 04 Aug 2016
PHARMAC updates its funding applications list
3 August 2016 - PHARMAC has published the funding applications received for PTAC for 2016. ...
Posted by Michael Wonder on 03 Aug 2016
Germany plans to extend price brake for drugs under statutory insurance
25 July 2016 - Germany wants to extend a price brake for drugs covered by statutory health insurance for five years ...
Posted by Michael Wonder on 03 Aug 2016
NICE issues draft guidance on the use of Otezla (apremilast)
3 August 2016 - NICE has issued draft guidance on the use of apremilast for the treatment of patients with moderate ...
Posted by Michael Wonder on 03 Aug 2016
Ramucirumab in gastric cancer: no sign of an additional clinical benefit
1 August 2016 - Former orphan drug undergoes regular early benefit assessment; submitted studies unsuitable for assessment. ...
Posted by Michael Wonder on 03 Aug 2016
Nivolumab in advanced lung cancer: evidence for significant additional benefits
1 August 2016 - Advantages in overall survival and side effects. ...
Posted by Michael Wonder on 03 Aug 2016
CADTH calls for patient input on a submission from Horizon Pharmaceuticals for Ravicti (glycerol phenylbutyrate)
2 August 2016 - CADTH has called for patient input from Horizon Pharmaceuticals for Ravicti. ...
Posted by Michael Wonder on 03 Aug 2016
Nivolumab in renal cell carcinoma: indication of additional clinical benefits
1 August 2016 - Benefits in overall survival, morbidity and side effects. ...
Posted by Michael Wonder on 03 Aug 2016
CADTH calls for patient input on submission from Allergan for Fetzima (levomilnacipran hydrochloride)
2 August 2016 - CADTH is calling for patient input on a pending submission from Allergan for Fetzima. ...
Posted by Michael Wonder on 02 Aug 2016
Rare cancer drug which significantly delays progression of advanced thyroid cancer is left off relaunched Cancer Drugs Fund
2 August 2016 - People with radioiodine refractory differentiated thyroid cancer are overlooked as Lenvima (lenvatinib mesylate) is not scheduled for ...
Posted by Michael Wonder on 02 Aug 2016
Call for NHS to haggle with drug companies over price of new treatments
1 August 2016 - Opposition politicians are calling for the Scottish NHS to haggle with drug companies over the price of ...
Posted by Michael Wonder on 02 Aug 2016
Afatinib dimaleate for patients with advanced squamous cell carcinoma of the lung: additional clinical benefits not there says IQWiG
1 August 2016 - Submitted comparisons for the benefit assessment are unsuitable. ...